Idexx Laboratories (IDXX) | Financial Analysis & Statements
Idexx Laboratories, Inc. Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
1.1B
Gross Profit
658.1M
60.35%
Operating Income
315.6M
28.94%
Net Income
248.2M
22.76%
EPS (Diluted)
$3.08
Balance Sheet Metrics
Total Assets
3.4B
Total Liabilities
1.7B
Shareholders Equity
1.6B
Debt to Equity
1.09
Cash Flow Metrics
Operating Cash Flow
353.3M
Free Cash Flow
326.1M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Idexx Laboratories Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 4.3B | 3.9B | 3.7B | 3.4B | 3.2B |
| Cost of Goods Sold | 1.6B | 1.5B | 1.5B | 1.4B | 1.3B |
| Gross Profit | 2.7B | 2.4B | 2.2B | 2.0B | 1.9B |
| Gross Margin % | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% |
| Operating Expenses | |||||
| Research & Development | 251.2M | 219.8M | 191.0M | 254.8M | 161.0M |
| Selling, General & Administrative | 1.0B | 1.0B | 901.9M | 850.8M | 796.4M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 1.3B | 1.3B | 1.1B | 1.1B | 957.4M |
| Operating Income | 1.4B | 1.1B | 1.1B | 898.8M | 932.0M |
| Operating Margin % | 31.6% | 29.0% | 30.0% | 26.7% | 29.0% |
| Non-Operating Items | |||||
| Interest Income | 3.0M | 12.7M | 5.6M | 1.1M | 434.0K |
| Interest Expense | 38.9M | 31.2M | 41.6M | 39.9M | 29.8M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 1.3B | 1.1B | 1.1B | 860.0M | 902.7M |
| Income Tax | 264.7M | 222.0M | 216.1M | 180.9M | 157.8M |
| Effective Tax Rate % | 20.0% | 20.0% | 20.4% | 21.0% | 17.5% |
| Net Income | 1.1B | 887.9M | 845.0M | 679.1M | 744.8M |
| Net Margin % | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% |
| Key Metrics | |||||
| EBITDA | 1.5B | 1.3B | 1.2B | 1.0B | 1.0B |
| EPS (Basic) | $13.17 | $10.77 | $10.17 | $8.12 | $8.74 |
| EPS (Diluted) | $13.08 | $10.67 | $10.06 | $8.03 | $8.60 |
| Basic Shares Outstanding | 80427000 | 82467000 | 83066000 | 83623000 | 85200000 |
| Diluted Shares Outstanding | 80427000 | 82467000 | 83066000 | 83623000 | 85200000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Idexx Laboratories Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 180.1M | 288.3M | 453.9M | 112.5M | 144.5M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | 552.4M | 473.6M | 457.4M | 400.6M | 368.3M |
| Inventory | 377.8M | 381.9M | 380.3M | 367.8M | 269.0M |
| Other Current Assets | 31.3M | 48.2M | 29.1M | 37.7M | 12.7M |
| Total Current Assets | 1.4B | 1.4B | 1.5B | 1.1B | 955.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 123.2M | 116.1M | 115.5M | 118.6M | 105.1M |
| Goodwill | 937.9M | 921.9M | 816.4M | 821.3M | 817.7M |
| Intangible Assets | 109.8M | 111.7M | 84.5M | 97.7M | 99.0M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 484.0M | 489.8M | 440.3M | 362.2M | 311.8M |
| Total Non-Current Assets | 1.9B | 1.9B | 1.8B | 1.6B | 1.5B |
| Total Assets | 3.4B | 3.3B | 3.3B | 2.7B | 2.4B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 110.4M | 114.2M | 110.6M | 110.2M | 116.1M |
| Short-term Debt | 500.1M | 439.3M | 344.8M | 674.4M | 168.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 1.1B | 1.1B | 951.5M | 1.2B | 763.6M |
| Non-Current Liabilities | |||||
| Long-term Debt | 476.0M | 547.6M | 722.6M | 795.6M | 862.6M |
| Deferred Tax Liabilities | 31.9M | 11.3M | 7.2M | 8.2M | 8.9M |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 596.6M | 630.2M | 823.8M | 902.2M | 983.6M |
| Total Liabilities | 1.7B | 1.7B | 1.8B | 2.1B | 1.7B |
| Equity | |||||
| Common Stock | 10.8M | 10.8M | 10.8M | 10.7M | 10.7M |
| Retained Earnings | 6.4B | 5.3B | 4.4B | 3.6B | 2.9B |
| Treasury Stock | 6.6B | 5.3B | 4.5B | 4.4B | 3.6B |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.6B | 1.6B | 1.5B | 608.7M | 690.0M |
| Key Metrics | |||||
| Total Debt | 976.1M | 986.9M | 1.1B | 1.5B | 1.0B |
| Working Capital | 265.0M | 332.0M | 543.7M | -134.3M | 192.1M |
Balance Sheet Composition
Idexx Laboratories Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 1.1B | 887.9M | 845.0M | 679.1M | 744.8M |
| Depreciation & Amortization | 145.2M | 129.9M | 114.9M | 111.9M | 104.6M |
| Stock-Based Compensation | 60.0M | 60.3M | 59.7M | 49.8M | 37.8M |
| Working Capital Changes | -227.5M | -133.2M | -72.4M | -273.5M | -137.5M |
| Operating Cash Flow | 1.2B | 921.9M | 899.5M | 534.8M | 748.9M |
| Investing Activities | |||||
| Capital Expenditures | -124.7M | -120.9M | -133.6M | -148.8M | -119.5M |
| Acquisitions | -756.0K | -77.7M | 0 | -36.5M | -173.4M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | 2.7M | 1.6M | 8.4M | 0 | 0 |
| Investing Cash Flow | -122.7M | -197.1M | -125.3M | -185.4M | -293.0M |
| Financing Activities | |||||
| Share Repurchases | -1.2B | -837.0M | -71.9M | -819.7M | -746.8M |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 250.0M | - | - | 0 | 0 |
| Debt Repayment | -428.4M | -75.0M | -75.0M | -75.0M | -50.0M |
| Financing Cash Flow | -1.3B | -922.6M | -489.0M | -406.7M | -744.0M |
| Free Cash Flow | 1.0B | 798.1M | 772.9M | 384.1M | 636.0M |
| Net Change in Cash | -207.6M | -197.7M | 285.2M | -57.2M | -288.0M |
Cash Flow Trend
Idexx Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
42.92
Forward P/E
34.19
Price to Book
27.85
Price to Sales
10.38
PEG Ratio
2.41
Profitability Ratios
Profit Margin
24.62%
Operating Margin
29.76%
Return on Equity
66.20%
Return on Assets
25.59%
Financial Health
Current Ratio
1.23
Debt to Equity
60.83
Beta
1.72
Per Share Data
EPS (TTM)
$13.07
Book Value per Share
$20.14
Revenue per Share
$53.51
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| IDXX | 44.7B | 42.92 | 27.85 | 66.20% | 24.62% | 60.83 |
| Thermo Fisher | 174.6B | 25.84 | 3.31 | 13.52% | 15.15% | 82.91 |
| Danaher | 126.4B | 34.61 | 2.40 | 7.08% | 14.89% | 37.17 |
| Agilent Technologies | 32.7B | 25.67 | 4.76 | 19.95% | 18.26% | 51.39 |
| Waters | 30.5B | 28.90 | 7.24 | 29.28% | 20.30% | 60.28 |
| Natera | 27.4B | - | 15.75 | -14.32% | -9.03% | 12.52 |
Financial data is updated regularly. All figures are in the company's reporting currency.






